Artem Dmitrievich Izyumchenko

Mr. Artem Dmitrievich Izyumchenko

Molecular Genetic and Nanobiological Technologies, First Pavlov State Medical University of St. Petersburg, Saint Petersburg, Sankt-Peterburg, Russia
+1
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
AKAlena Kopytova
Alena Kopytova
GRGeorgy N. Rychkov
Georgy N. Rychkov
ACAlexander A. Cheblokov
Alexander A. Cheblokov
EGElena Grigor'eva
Elena Grigor'eva
MNMikhael Nikolaev
Mikhael Nikolaev
AEAnton K. Emelyanov
Anton K. Emelyanov
Mutations in the GBA1 gene, encoding the lysosomal enzyme glucocerebrosidase (GCase), cause Gaucher disease (GD) and are the most common genetic risk factor for Parkinson’s disease (PD). Pharmacological chaperones (PCs) are being developed as an alternative treatment approach for GD and PD. To date, NCGC00241607 (NCGC607) is one of the most promising PCs. Using molecular docking and molecular dynamics simulation we identified and characterized six allosteric binding sites on the GCase surface suitable for PCs. Two sites were energetically more preferable for NCGC607 and located nearby to the active site of the enzyme. We evaluated the effects of NCGC607 treatment on GCase activity and protein levels, glycolipids concentration in cultured macrophages from GD (n = 9) and GBA-PD (n = 5) patients as well as in induced human pluripotent stem cells (iPSC)—derived dopaminergic (DA) neurons from GBA-PD patient. The results showed that NCGC607 treatment increased GCase activity (by 1.3-fold) and protein levels (by 1.5-fold), decreased glycolipids concentration (by 4.0-fold) in cultured macrophages derived from GD patients and also enhanced GCase activity (by 1.5-fold) in cultured macrophages derived from GBA-PD patients with N370S mutation (p < 0.05). In iPSC-derived DA neurons from GBA-PD patients with N370S mutation NCGC607 treatment increased GCase activity and protein levels by 1.1-fold and 1.7-fold (p < 0.05). Thus, our results showed that NCGC607 could bind to allosteric sites on the GCase surface and confirmed its efficacy on cultured macrophages from GD and GBA-PD patients as well as on iPSC-derived DA neurons from GBA-PD patients.

10 December 2021 in Cells
Verified
Journal Article
Open access
PDF file
IVIvan Vlasov
Ivan Vlasov
APAlexandra Panteleeva
Alexandra Panteleeva
TUTatiana Usenko
Tatiana Usenko
MNMikhael Nikolaev
Mikhael Nikolaev
AIArtem Dmitrievich Izyumchenko
Artem Dmitrievich Izyumchenko
Pyotr A. SlominskyPyotr A. Slominsky
Pyotr A. Slominsky
To assess the biology of the lethal endpoint in patients with SARS-CoV-2 infection, we compared the transcriptional response to the virus in patients who survived or died during severe COVID-19. We applied gene expression profiling to generate transcriptional signatures for peripheral blood mononuclear cells (PBMCs) from patients with SARS-CoV-2 infection at the time when they were placed in the Intensive Care Unit of the Pavlov First State Medical University of St. Petersburg (Russia). Three different bioinformatics approaches to RNA-seq analysis identified a downregulation of three common pathways in survivors compared with nonsurvivors among patients with severe COVID-19, namely, low-density lipoprotein (LDL) particle receptor activity (GO:0005041), important for maintaining cholesterol homeostasis, leukocyte differentiation (GO:0002521), and cargo receptor activity (GO:0038024). Specifically, PBMCs from surviving patients were characterized by reduced expression of PPARG, CD36, STAB1, ITGAV, and ANXA2. Taken together, our findings suggest that LDL particle receptor pathway activity in patients with COVID-19 infection is associated with poor disease prognosis.

Verified
Journal Article
Open access
PDF file
VMValentina V. Miroshnikova
Valentina V. Miroshnikova
PVPetr Vasilev
Petr Vasilev
SLSvetlana V. Linkova
Svetlana V. Linkova
VSVladislav M. Soloviov
Vladislav M. Soloviov
OIOlga N. Ivanova
Olga N. Ivanova
SPSofia Pchelina
Sofia Pchelina
Here, we report the pediatric cases of sitosterolemia, a rare autosomal-recessive genetic disorder, characterized by high concentrations of plant sterols in blood and heterogeneity manifestations. All three patients (two girls aged 2 and 6 years old, and one boy aged 14 years old) were initially diagnosed with hypercholesterinemia. Next-generation sequencing (NGS) revealed homozygous (p.Leu572Pro/p.Leu572Pro) and compound (p.Leu572Pro/p.Gly512Arg and p.Leu572Pro/p.Trp361*) variants in the ABCG8 gene that allowed for the diagnosis of sitosterolemia. Two patients whose blood phytosterol levels were estimated before the diet demonstrated high levels of sitosterol/campesterol (69.6/29.2 and 28.3/12.4 μmol/L, respectively). Here, we demonstrate that NGS-testing led to the proper diagnosis that is essential for patients’ management. The variant p.Leu572Pro might be prevalent among patients with sitosterolemia in Russia.

13 May 2022 in The Scientific Notes of the Pavlov University
Verified
Journal Article
Open access
PDF file
OSOlga Sirotkina
Olga Sirotkina
AUA. S. Ulitina
A. S. Ulitina
DKDaria Kulabukhova
Daria Kulabukhova
MNMikhael Nikolaev
Mikhael Nikolaev
AIArtem Dmitrievich Izyumchenko
Artem Dmitrievich Izyumchenko
SPSofia Pchelina
Sofia Pchelina
Introduction. In recent years, much attention has been paid to the study of extracellular microparticles (microvesicles and exosomes) and their role in the pathogenesis of human diseases.The objective of this study was to determine the number and size of plasma extracellular microparticles (PEMP) in patients with severe and extremely severe COVID-19 and correlate these data with the markers of hemostasis activation, inflammation, and tissue damage.Methods and Materials. The study included 29 patients with severe and extremely severe COVID-19. Concentration and size of PEMP were determined by nanoparticle trajectory analysis (NTA). All patients underwent the complete blood count and the thromboelastometry (TEM). Hemostatic, biochemical, and immunological parameters were assessed including fibrinogen, prothrombin time, activated partial thromboplastin time, D-dimer, C-reactive protein, lactate dehydrogenase, procalcitonin, von Willebrand factor antigen, interleukin 6, and interleukin 18.Results. There were 14 patients (48.3 %) discharged from the ICU with improvement (group 1— survived patients), and 15 patients (51.7 %) with lethal outcomes (group 2 — lethal outcome); the PEMP concentration did not differ between these groups. In group 2, there were heterogeneity of PEMP population, and a tendency to the larger PEMP size (p=0.074). In all patients, the PEMP concentration correlated negatively with both prothrombin time and the number of large platelets; the size of PEMP correlated negatively with the level of von Willebrand factor antigen, and positively with the fibrinogen. In group 1, the PEMP concentration had a direct correlation with both the level of interleukin 18 and maximum clot lysis in TEM; the PEMP size had a direct correlation with the maximum clot lysis in TEM and an inverse correlation with both the level of procalcitonin and maximum clot density in TEM.Conclusion. Our study confirms the importance of the process of extracellular microparticles formation in the COVID-19 pathogenesis. Our findings are consistent with the hypothesis that the parameters of PEMP population can be predictive biomarkers of the COVID-19 severity.

21 November 2025 in Russian Journal of Cardiology
Verified
Journal Article
Closed access
VMValentina V. Miroshnikova
Valentina V. Miroshnikova
AIArtem Dmitrievich Izyumchenko
Artem Dmitrievich Izyumchenko
MMM. V. Muzalevskaya
M. V. Muzalevskaya
KLK. V. Legostaeva
K. V. Legostaeva
MGMaria Grunina
Maria Grunina
SPSofia Pchelina
Sofia Pchelina
Aim. To determine the frequency of pathogenic and likely pathogenic variants associated with familial hypercholesterolemia (FH) with assessment of the proportion of polygenic FH according to the 6-SNP genetic risk score (GRS) among patients diagnosed with possible/probable/definite FH in St. Petersburg. Material and methods. This study tested a hybrid targeted panel for gene diagnostics of hereditary dyslipidemias, including an expanded list of genes associated with monogenic dyslipidemias and a number of single-nucleotide variants associated with polygenic hypercholesterolemia and cardiovascular risk. Genetic testing was performed on 125 patients. Results. A total of 26 pathogenic and likely pathogenic variants in the LDLR gene were identified in 38 patients, while 6 variants of uncertain clinical significance in the LDLR gene — in 7 patients, and a pathogenic variant 10580G>A (p.Arg3527G) in the APOB gene — in 6 patients. The highest detection rate of causal genetic variants (66,7%) was observed, as expected, in the subgroup of patients with definite FH. Patients with a high polygenic risk of hypercholesterolemia predominated in the subgroups diagnosed with possible and probable FH. Conclusion. The use of an expanded next-generation sequencing (NGS) panel, including genes for hereditary dyslipidemias, as well as loci for calculating the GRS, may be critical for differential diagnosis, determining the etiology of hypercholesterolemia, and personalizing treatment approaches.

26 May 2026 in Vavilov Journal of Genetics and Breeding
Verified
Journal Article
Open access
PDF file
AIArtem Dmitrievich Izyumchenko
Artem Dmitrievich Izyumchenko
MGM. N. Grunina
M. N. Grunina
KDK. V. Dracheva
K. V. Dracheva
OCO. A. Chumakova
O. A. Chumakova
KTK. O. Tanayants
K. O. Tanayants
VMV. V. Miroshnikova
V. V. Miroshnikova
Cardiovascular diseases are the leading cause of death both in Russia and in the world. One of the factors predisposing to the development of cardiovascular diseases is lipid metabolism disorders (dyslipidemias), which contribute to the progression of atherosclerosis. Currently, there are known genes associated with the development of monogenic forms of lipid metabolism disorders characterized by marked changes in lipid levels. However, identifying individuals with an increased genetic risk of dyslipidemia remains an unsolved problem, due to the polygenic nature of most cases. The aim of this work was to study the spectrum of rare variants in the cholesterol transporter genes ABCA1 , ABCG1 , ABCG5 , ABCG8 and NPC1L1 that occur in patients with lipid metabolism disorders in the population of the Northwestern region of Russia. The search for rare variants (gnomAD frequency less than 1 %) in the ABCA1 , ABCG1 , ABCG5 , ABCG8 and NPC1L1 genes was performed using targeted sequencing data for 169 patients with lipid metabolism disorders. 14 variants were identified in the ABCA1 gene (17 patients); 4 variants, in the ABCG1 gene (5 patients); 11 variants, in the ABCG5 gene (18 patients); and 7 variants, in the ABCG8 gene (11 patients). The frequency of some of them, according to the RUSeq database, is higher than in the global population. 19 patients (11 %) were carriers of the p.(Val177Ile)/p.(His221Tyr)/p.(Ala271Phe) haplotype in the NPC1L1 gene, which may be specific to the Russian population, meaning that these variants are not rare, but polymorphic, and occur more frequently in patients with impaired lipid metabolism. Influence of the p.(Val177Ile) variant of the NPC1L1 gene on the development of atherosclerosis was assessed using additional sample sets (a group of patients with atherosclerosis, a control group), but no significant differences in genotype frequencies were revealed. Thus, at present, there are insufficient data to support the role of the p.(Val177Ile)/p.(His221Tyr)/p.(Ala271Phe) haplotype of the NPC1L1 gene in the development of dyslipidemia and atherosclerosis. The study draws attention to the population specificity of a number of variants in cholesterol transporter genes, in particular in the NPC1L1 gene, for the Northwestern region of Russia. The data can be further used for design and calculation of genetic risk scores for dyslipidemia.